On December 20 2024, Zonhonbio reported its class 1 innovative biological drug, ZHB015 for injection, has received the "Clinical Trial Approval Notice" from China’s NAtional medical products administration (NMPA) (Press release, Zonhon Biopharma Institute, DEC 20, 2024, View Source [SID1234656086]). ZHB015 for injection is an original research and development by Zonhonbio, with completely independent intellectual property rights both domestically and internationally. It is a bispecific antibody drug developed using innovative targets and has been approved for use in advanced malignant solid tumors.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!